DS
TGTX icon

David Shaw’s TG Therapeutics TGTX Stock Holding History

David Shaw’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187M Buy
3,400,808
+2,810,761
+476% +$115M 0.09% 237
2026
Q1 		$19.6M Sell
590,047
-110,298
-16% -$3.29M 0.01% 1156
2025
Q4 		$20.9M Buy
700,345
+468,322
+202% +$15.3M 0.01% 1222
2025
Q3 		$8.38M Buy
232,023
+113,886
+96% +$3.75M ﹤0.01% 1819
2025
Q2 		$4.25M Buy
118,137
+56,207
+91% +$2.09M ﹤0.01% 2150
2025
Q1 		$2.44M Sell
61,930
-106,573
-63% -$3.59M ﹤0.01% 2459
2024
Q4 		$5.07M Sell
168,503
-226,276
-57% -$6.49M ﹤0.01% 1970
2024
Q3 		$9.23M Buy
394,779
+154,767
+64% +$3.38M 0.01% 1475
2024
Q2 		$4.27M Buy
240,012
+150,410
+168% +$2.4M ﹤0.01% 1978
2024
Q1 		$1.36M Sell
89,602
-173,176
-66% -$2.76M ﹤0.01% 2896
2023
Q4 		$4.49M Buy
262,778
+127,581
+94% +$1.48M ﹤0.01% 1991
2023
Q3 		$1.13M Sell
135,197
-1,440,274
-91% -$20.1M ﹤0.01% 2988
2023
Q2 		$39.1M Buy
1,575,471
+741,694
+89% +$19.2M 0.04% 535
2023
Q1 		$12.5M Sell
833,777
-1,370,453
-62% -$20.8M 0.01% 1196
2022
Q4 		$26.1M Buy
2,204,230
+1,503,230
+214% +$10.9M 0.03% 753
2022
Q3 		$4.15M Sell
701,000
-512,778
-42% -$3.36M 0.01% 2300
2022
Q2 		$5.16M Buy
1,213,778
+943,427
+349% +$5.89M 0.01% 2085
2022
Q1 		$2.57M Buy
270,351
+253,317
+1,487% +$2.93M ﹤0.01% 3052
2021
Q4 		$324K Sell
17,034
-2,404
-12% -$62.4K ﹤0.01% 4645
2021
Q3 		$647K Sell
19,438
-138,142
-88% -$4.27M ﹤0.01% 3919
2021
Q2 		$6.11M Sell
157,580
-377,421
-71% -$14.8M 0.01% 1882
2021
Q1 		$25.8M Sell
535,001
-333,478
-38% -$16M 0.02% 796
2020
Q4 		$45.2M Buy
868,479
+344,892
+66% +$11.7M 0.04% 537
2020
Q3 		$14M Buy
523,587
+263,544
+101% +$6.06M 0.01% 1021
2020
Q2 		$5.07M Sell
260,043
-21,850
-8% -$352K 0.01% 1657
2020
Q1 		$2.77M Sell
281,893
-604,195
-68% -$7.63M ﹤0.01% 1911
2019
Q4 		$9.84M Buy
886,088
+707,522
+396% +$5.38M 0.01% 1211
2019
Q3 		$1M Buy
178,566
+90,697
+103% +$632K ﹤0.01% 2829
2019
Q2 		$760K Sell
87,869
-185,698
-68% -$1.4M ﹤0.01% 2838
2019
Q1 		$2.2M Buy
273,567
+200,553
+275% +$1.08M ﹤0.01% 2094
2018
Q4 		$300K Buy
73,014
+58,573
+406% +$291K ﹤0.01% 3346
2018
Q3 		$81K Sell
14,441
-243,133
-94% -$2.78M ﹤0.01% 3629
2018
Q2 		$3.39M Buy
257,574
+62,050
+32% +$853K ﹤0.01% 1813
2018
Q1 		$2.78M Buy
195,524
+107,253
+122% +$1.37M ﹤0.01% 1814
2017
Q4 		$724K Sell
88,271
-51,085
-37% -$446K ﹤0.01% 2760
2017
Q3 		$1.65M Buy
139,356
+78,019
+127% +$889K ﹤0.01% 2169
2017
Q2 		$616K Buy
61,337
+15,624
+34% +$175K ﹤0.01% 2711
2017
Q1 		$533K Buy
+45,713
New +$328K ﹤0.01% 2698
2015
Q3 		– Sell
-81,342
Closed -$1.35M – 3890
2015
Q2 		$1.35M Buy
81,342
+19,996
+33% +$317K ﹤0.01% 2486
2015
Q1 		$950K Buy
+61,346
New +$929K ﹤0.01% 2594

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's TGTX Position: Q2 2026 in Review

David Shaw increased its TG Therapeutics (TGTX) stake by 476% in Q2 2026, buying an estimated $115M and bringing the position to 3,400,808 shares worth $187M. The position accounts for 0.09% of the portfolio, ranked #237.

David Shaw first reported a position in TGTX in Q1 2015 and has held it in 40 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • David Shaw held 3,400,808 shares of TG Therapeutics worth $187M as of Q2 2026.
  • David Shaw bought 2,810,761 TG Therapeutics shares in Q2 2026, an estimated $115M.
  • TG Therapeutics made up 0.09% of David Shaw's portfolio in Q2 2026, its #237 holding.
  • David Shaw first reported a position in TG Therapeutics in Q1 2015 and has held it in 40 quarters since.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.